Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 33Unknown 2Terminated 2Recruiting 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 4Thoracic 2Sarcoma 2Other hematologic neoplasm 2Dermatologic 2Breast 2Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 2Unilateral Breast Neoplasms 1Inflammatory Breast Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 83Fulvestrant 65Trastuzumab 62Letrozole 61pembrolizumab 53Carboplatin 51Cyclophosphamide 48pertuzumab 46palbociclib 44Anastrozole 41Capecitabine 33Tamoxifen 30Magnetic Resonance Spectroscopy 29exemestane 28Radiotherapy 28Doxorubicin 28ribociclib 26olaparib 26Docetaxel 26Specimen Handling 25abemaciclib 24130-nm albumin-bound paclitaxel 20trastuzumab deruxtecan 19Taxes 19Gemcitabine 19durvalumab 18Surveys and Questionnaires 18Epirubicin 18eribulin 17Alpelisib 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × sargramostim × Breast × Clear all
NCT05455658 2026-05-05

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

University of Washington

Phase 2 Active not recruiting
33 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03012100 2023-01-13

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Academic and Community Cancer Research United

Phase 2 Active not recruiting
280 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡